SEC Form 10-Q filed by TuHURA Biosciences Inc.
$HURA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/3/2025 | $13.00 | Buy | H.C. Wainwright |
| 12/19/2024 | $11.00 | Buy | Rodman & Renshaw |
| 11/5/2024 | $15.00 | Buy | Maxim Group |
Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing
Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer immunotherapy The first demonstration that DOR is expressed on Tumor-Associated Macrophages (TAMs), with DOR inhibition modulating their immunosuppressive capabilities Presentation from The Moffitt Cancer Center in collaboration with TuHURA scientists demonstrating the presence of the DOR on MDSCs from patients with myeloid dysplastic syndrome (MDS) and restoration of stem cell proliferation with DOR inhibition TAMPA
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City. James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows: 27th Annual H.C. Wainwright Global Investment Conference Date: Monday, September 8, 2025 Time: 2:30 PM Eastern Time Link: Click Here A replay of the presenta
H.C. Wainwright initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $13.00
Rodman & Renshaw initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $11.00
Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00
4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
3 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
10-Q - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
D - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing
Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceutic
Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco
SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)
SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)
SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)